Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A recent publication in BMC Infectious Diseases concerning the use of convalescent plasma for the treatment of COVID-19 had a number of major issues. This correspondence details specific instances of unclear reporting as well as major omissions when discussing the context of the trial. These render the study's findings and conclusions misleading.

Original publication

DOI

10.1186/s12879-022-07551-8

Type

Journal article

Journal

BMC Infect Dis

Publication Date

22/06/2022

Volume

22

Keywords

Convalescent Plasma, Covid-19, Trial Registration, Trial Reporting, Trials Transparency, COVID-19, Humans, Immunization, Passive